Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,retainedEarnings,otherLiab,treasuryStock,otherAssets,cash,totalCurrentLiabilities,deferredLongTermAssetCharges,shortLongTermDebt,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,longTermInvestments,shortTermInvestments,netReceivables,longTermDebt,accountsPayable,otherCurrentAssets,changeToLiabilities,totalCashflowsFromInvestingActivities,netBorrowings,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,effectOfExchangeRate,totalCashFromOperatingActivities,depreciation,otherCashflowsFromInvestingActivities,changeToAccountReceivables,otherCashflowsFromFinancingActivities,changeToNetincome,capitalExpenditures,investments,WC,language,region,quoteType,triggerable,quoteSourceName,currency,epsTrailingTwelveMonths,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,priceHint,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,messageBoardId,marketState,shortName,market,exchangeDataDelayedBy,exchange,esgPopulated,tradeable,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,Shares Short 4,Short Ratio 4,Short % of Float 4,Short % of Shares Outstanding 4,Shares Short (prior month ) 4,Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,compensationRisk,auditRisk,longBusinessSummary,city,phone,shareHolderRightsRisk,compensationAsOfEpochDate,governanceEpochDate,boardRisk,country,website,maxAge,overallRisk,address1,fax,industry,address2
t0,IPHYF,109687000.0,79027504,,,-26825000,,-26825000,8378000,3296000,-5099500,-5099500,17500,-84000,,,,0,16853000,21952500,13557000,-21725500,,-26825000,-26825000,46289000.0,372131000.0,151447000.0,155976000.0,22615000.0,307423000.0,3950000.0,-220460000.0,89014000.0,355000.0,37055000.0,136792000.0,45488000.0,7087000.0,1365000.0,355000.0,11694000.0,173451000.0,38934000.0,14845000.0,21814000.0,14188000.0,20731000.0,,-7021000.0,-631000.0,72000.0,11000.0,17336000.0,22500.0,2624500.0,116000.0,3129000.0,3274500.0,98500.0,-6120500.0,-83500.0,22485000.0,-181500.0,,127963000.0,en-US,US,EQUITY,False,Delayed Quote,USD,-0.968,1.975,3.2534285,0.40657163,0.124967135,3.9062319,-0.2462318,-0.06303563,289240672,1.8531646,15,America/New_York,EDT,-14400000,4,3.0985954,3.66 - 3.66,3.55,finmb_426137,PRE,INNATE PHARMA,us_market,0,PNK,False,False,3.66,1630503006,0.11000013,3.66,3.66,3.66,100,Other OTC,Innate Pharma S.A.,EUR,243,14,0.51,0.16190475,3.15 - 6.5,-2.84,-0.43692306,3.15,6.5,0.11,,,6.5,3.15,3.2534,3.9062,243,14,79.03M,,51.13M,24.72%,21.19%,,,,,,,,,,,0.00%,,,,,"Dec 30, 2020","Dec 30, 2020",-90.82%,-26.33%,-3.27%,-34.27%,70.45M,0.89,26.40%,11.84M,-6.32M,-63.98M,-0.9680,,151.64M,1.92,19.09M,12.24,3.81,1.98,-51.77M,-86.76M,Value,13009,Healthcare,244,10,8,"Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sÃ©zary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase II clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; Avdoralimab (IPH5401), a monoclonal antibody blocking C5a binding to C5aR1 that is in Phase II clinicals trials for the treatment of COVID-19, bullous pemphigoid, chronic spontaneous urticaria, and other inflammatory diseases; and IPH5201, a blocking antibody that is in Phase 1 clinical trials targeting the CD39 immunosuppressive pathway. Its products in preclinical trials include IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH61, NKp46-based NK cell engager for the generation and evaluation of up to two bispecific NK cell engagers; IPH43, an anti-MICA/B antibody drug conjugate; Lumoxiti (moxetumomab pasudotox-tdfk), a tumor antigen targeting solution for the treatment of hairy cell leukemia; Anti-Siglec-9, an antibody program; IPH25, a checkpoint inhibitor; and IPH62, an NKp46-NKCE platform. Innate Pharma S.A. has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. The company was incorporated in 1999 and is headquartered in Marseille, France.",Marseille,33 4 30 30 30 30,3,1609372800,1625097600,6,France,http://www.innate-pharma.com,86400,8,"117, Avenue de Luminy",33 4 30 30 30 00,Biotechnology,BP 30191
t-1,IPHYF,109687000.0,79027504,,,-26825000,,-26825000,8378000,3296000,-5099500,-5099500,17500,-84000,,,,0,16853000,21952500,13557000,-21725500,,-26825000,-26825000,46289000.0,372131000.0,151447000.0,155976000.0,22615000.0,307423000.0,3950000.0,-220460000.0,89014000.0,355000.0,37055000.0,136792000.0,45488000.0,7087000.0,1365000.0,355000.0,11694000.0,173451000.0,38934000.0,14845000.0,21814000.0,14188000.0,20731000.0,,-7021000.0,-631000.0,72000.0,11000.0,17336000.0,22500.0,2624500.0,116000.0,3129000.0,3274500.0,98500.0,-6120500.0,-83500.0,22485000.0,-181500.0,,127963000.0,en-US,US,EQUITY,False,Delayed Quote,USD,-0.968,1.975,3.2534285,0.40657163,0.124967135,3.9062319,-0.2462318,-0.06303563,289240672,1.8531646,15,America/New_York,EDT,-14400000,4,3.0985954,3.66 - 3.66,3.55,finmb_426137,PRE,INNATE PHARMA,us_market,0,PNK,False,False,3.66,1630503006,0.11000013,3.66,3.66,3.66,100,Other OTC,Innate Pharma S.A.,EUR,243,14,0.51,0.16190475,3.15 - 6.5,-2.84,-0.43692306,3.15,6.5,0.11,,,6.5,3.15,3.2534,3.9062,243,14,79.03M,,51.13M,24.72%,21.19%,,,,,,,,,,,0.00%,,,,,"Dec 30, 2020","Dec 30, 2020",-90.82%,-26.33%,-3.27%,-34.27%,70.45M,0.89,26.40%,11.84M,-6.32M,-63.98M,-0.9680,,151.64M,1.92,19.09M,12.24,3.81,1.98,-51.77M,-86.76M,Value,13009,Healthcare,244,10,8,"Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sÃ©zary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase II clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; Avdoralimab (IPH5401), a monoclonal antibody blocking C5a binding to C5aR1 that is in Phase II clinicals trials for the treatment of COVID-19, bullous pemphigoid, chronic spontaneous urticaria, and other inflammatory diseases; and IPH5201, a blocking antibody that is in Phase 1 clinical trials targeting the CD39 immunosuppressive pathway. Its products in preclinical trials include IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH61, NKp46-based NK cell engager for the generation and evaluation of up to two bispecific NK cell engagers; IPH43, an anti-MICA/B antibody drug conjugate; Lumoxiti (moxetumomab pasudotox-tdfk), a tumor antigen targeting solution for the treatment of hairy cell leukemia; Anti-Siglec-9, an antibody program; IPH25, a checkpoint inhibitor; and IPH62, an NKp46-NKCE platform. Innate Pharma S.A. has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. The company was incorporated in 1999 and is headquartered in Marseille, France.",Marseille,33 4 30 30 30 30,3,1609372800,1625097600,6,France,http://www.innate-pharma.com,86400,8,"117, Avenue de Luminy",33 4 30 30 30 00,Biotechnology,BP 30191
t-2,IPHYF,112549000.0,79027504,,,-5167000,,-5167000,7245000,2623000,-4174000,-4174000,-448000,-86500,,,,0,18372500,22546500,15749500,-993000,,-5167000,-5167000,95215000.0,370440000.0,125302000.0,207764000.0,60198000.0,333066000.0,3946000.0,-166053000.0,26176000.0,-569000.0,24856000.0,131542000.0,82345000.0,1269000.0,1289000.0,-569000.0,12434000.0,163689000.0,36872000.0,16199000.0,6062000.0,13712000.0,20112000.0,577000.0,-18812500.0,-6054000.0,-514500.0,-599500.0,-4646000.0,1500.0,-35672500.0,-6500.0,-29012500.0,3359500.0,353000.0,-5339000.0,-86500.0,1592500.0,-272000.0,-1500000.0,81344000.0,en-US,US,EQUITY,False,Delayed Quote,USD,-0.968,1.975,3.2534285,0.40657163,0.124967135,3.9062319,-0.2462318,-0.06303563,289240672,1.8531646,15,America/New_York,EDT,-14400000,4,3.0985954,3.66 - 3.66,3.55,finmb_426137,PRE,INNATE PHARMA,us_market,0,PNK,False,False,3.66,1630503006,0.11000013,3.66,3.66,3.66,100,Other OTC,Innate Pharma S.A.,EUR,243,14,0.51,0.16190475,3.15 - 6.5,-2.84,-0.43692306,3.15,6.5,0.11,,,6.5,3.15,3.2534,3.9062,243,14,79.03M,,51.13M,24.72%,21.19%,,,,,,,,,,,0.00%,,,,,"Dec 30, 2020","Dec 30, 2020",-90.82%,-26.33%,-3.27%,-34.27%,70.45M,0.89,26.40%,11.84M,-6.32M,-63.98M,-0.9680,,151.64M,1.92,19.09M,12.24,3.81,1.98,-51.77M,-86.76M,Value,13009,Healthcare,244,10,8,"Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sÃ©zary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase II clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; Avdoralimab (IPH5401), a monoclonal antibody blocking C5a binding to C5aR1 that is in Phase II clinicals trials for the treatment of COVID-19, bullous pemphigoid, chronic spontaneous urticaria, and other inflammatory diseases; and IPH5201, a blocking antibody that is in Phase 1 clinical trials targeting the CD39 immunosuppressive pathway. Its products in preclinical trials include IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH61, NKp46-based NK cell engager for the generation and evaluation of up to two bispecific NK cell engagers; IPH43, an anti-MICA/B antibody drug conjugate; Lumoxiti (moxetumomab pasudotox-tdfk), a tumor antigen targeting solution for the treatment of hairy cell leukemia; Anti-Siglec-9, an antibody program; IPH25, a checkpoint inhibitor; and IPH62, an NKp46-NKCE platform. Innate Pharma S.A. has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. The company was incorporated in 1999 and is headquartered in Marseille, France.",Marseille,33 4 30 30 30 30,3,1609372800,1625097600,6,France,http://www.innate-pharma.com,86400,8,"117, Avenue de Luminy",33 4 30 30 30 00,Biotechnology,BP 30191
t-3,IPHYF,112549000.0,79027504,,,-5167000,,-5167000,7245000,2623000,-4174000,-4174000,-448000,-86500,,,,0,18372500,22546500,15749500,-993000,,-5167000,-5167000,95215000.0,370440000.0,125302000.0,207764000.0,60198000.0,333066000.0,3946000.0,-166053000.0,26176000.0,-569000.0,24856000.0,131542000.0,82345000.0,1269000.0,1289000.0,-569000.0,12434000.0,163689000.0,36872000.0,16199000.0,6062000.0,13712000.0,20112000.0,577000.0,-18812500.0,-6054000.0,-514500.0,-599500.0,-4646000.0,1500.0,-35672500.0,-6500.0,-29012500.0,3359500.0,353000.0,-5339000.0,-86500.0,1592500.0,-272000.0,-1500000.0,81344000.0,en-US,US,EQUITY,False,Delayed Quote,USD,-0.968,1.975,3.2534285,0.40657163,0.124967135,3.9062319,-0.2462318,-0.06303563,289240672,1.8531646,15,America/New_York,EDT,-14400000,4,3.0985954,3.66 - 3.66,3.55,finmb_426137,PRE,INNATE PHARMA,us_market,0,PNK,False,False,3.66,1630503006,0.11000013,3.66,3.66,3.66,100,Other OTC,Innate Pharma S.A.,EUR,243,14,0.51,0.16190475,3.15 - 6.5,-2.84,-0.43692306,3.15,6.5,0.11,,,6.5,3.15,3.2534,3.9062,243,14,79.03M,,51.13M,24.72%,21.19%,,,,,,,,,,,0.00%,,,,,"Dec 30, 2020","Dec 30, 2020",-90.82%,-26.33%,-3.27%,-34.27%,70.45M,0.89,26.40%,11.84M,-6.32M,-63.98M,-0.9680,,151.64M,1.92,19.09M,12.24,3.81,1.98,-51.77M,-86.76M,Value,13009,Healthcare,244,10,8,"Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sÃ©zary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase II clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; Avdoralimab (IPH5401), a monoclonal antibody blocking C5a binding to C5aR1 that is in Phase II clinicals trials for the treatment of COVID-19, bullous pemphigoid, chronic spontaneous urticaria, and other inflammatory diseases; and IPH5201, a blocking antibody that is in Phase 1 clinical trials targeting the CD39 immunosuppressive pathway. Its products in preclinical trials include IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH61, NKp46-based NK cell engager for the generation and evaluation of up to two bispecific NK cell engagers; IPH43, an anti-MICA/B antibody drug conjugate; Lumoxiti (moxetumomab pasudotox-tdfk), a tumor antigen targeting solution for the treatment of hairy cell leukemia; Anti-Siglec-9, an antibody program; IPH25, a checkpoint inhibitor; and IPH62, an NKp46-NKCE platform. Innate Pharma S.A. has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. The company was incorporated in 1999 and is headquartered in Marseille, France.",Marseille,33 4 30 30 30 30,3,1609372800,1625097600,6,France,http://www.innate-pharma.com,86400,8,"117, Avenue de Luminy",33 4 30 30 30 00,Biotechnology,BP 30191
